Endologix shares dropped sharply on news of a temporary hold on the shipments of its abdominal aortic aneurysms products, but now that the company is resuming shipments, the stock has recovered somewhat.
Shares of Cempra were halved on Thursday after the company received a Complete Response Letter from the U.S. Food and Drug Administration (FDA).
Galena Biopharma, Inc. (NASDAQ: GALE) saw its shares jump on Wednesday after a key U.S. Food and Drug Administration (FDA) approval. The company announced that it has confirmed the regulatory pathway to advance GALE-401…
The December 15 short interest data have been compared with the previous figures, and short interest increased in most of these selected pharmaceutical stocks.
The December 15 short interest data have been compared with the previous report, and short interest was down in most of the selected biotech stocks.
The cities where life expectancies are the shortest tend to report lower household incomes and more unhealthy behaviors than cities with longer life expectancies.
The SEC has announced that Teva Pharmaceutical Industries has agreed to pay over $519 million to settle charges that it violated the Foreign Corrupt Practices Act by paying bribes to foreign government officials.
Drugmakers' stocks can get clobbered by regulatory investigations. That's what happened to this year's least successful company: Endo International, which has seen its share price fall by more than 73%.
These 10 cities had the longest life expectancies in the entire United States. They tend to have certain characteristics common.
Shares of Amphastar Pharmaceuticals fell on Tuesday after the company announced that a subsidiary had received a Complete Response Letter from the FDA.
Although the week between Christmas and New Year’s is not a heavily traded one, one company is making a case for it with a double-digit move on Tuesday.
Seattle Genetics shares were down double-digits after the company announced that the FDA has placed holds on several early-stage clinical trials of its leukemia drug candidate.
Visterra has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
In a new research report, the biotech team at RBC reveal their top picks for 2017, and while hardly pounding the table, they are cautiously optimistic.
Shares of Merrimack Pharmaceuticals dropped on Wednesday after the company reported that it would stop a mid-stage cancer study.
